The News Review:
- Hospitals That Participate In Clinical Trials May Provide Better…
- Certain Liver Disease Related To Cardiovascular Fitness
- Green Light for Purple Pill
- Bloomberg.com: Investment Tools
- New academy launched to promote best practices in pharmaceutical…
- Supreme Court rules on insurance coverage
- Medivation Announces Senior Management Promotions
Hospitals That Participate In Clinical Trials May Provide Better…
Science Daily – Science Daily (press release) – Mar 25, 2008
"Journal reference: Arch Intern Med. 2008;168[6]:657-662. Majumdar receives salary support awards from the Alberta Heritage Foundation for Medical Research (Health Scholar) and the Canadian Institutes of Health Research (New Investigator). Adapted from materials provided by.
Certain Liver Disease Related To Cardiovascular Fitness
Science Daily – Science Daily (press release) – Mar 25, 2008
Future studies should include a randomized controlled trial of exercise training that can reveal its direct effects on NAFLD histopathology they suggest. “In the meantime it would appear rational and prudent for healthcare providers to recommend exercise training to improve health-related fitness as an integral role in the care of patients with NAFLD” they conclude. This work was conducted as an ancillary study of the NAFLD Clinical Research Network a national research consortium funded by the National Institutes of Health. Journal reference: “Health-Related Fitness and Physical Activity in Patients with Nonalcoholic Fatty Liver Disease. ” Krasnoff Joanne; Painter Patricia; Wallace Janet; Bass Nathan; Merriman Raphael. Hepatology; April 2008; 10.
Green Light for Purple Pill
Washington Post – Mar 25, 2008
But such “off-label” prescriptions can be tricky particularly in children in whom drugs do not always act as they do in adults even when doctors try to adjust for body weight and metabolism. About 100 adult drugs have been approved for pediatric use since 1997. Before it conducted the new research AstraZeneca had already received an extension on Nexium’s patents (which expire between 2014 and 2018) for earlier clinical research. As a result of the company’s studies Nexium dosage for kids was set at 10 to 20 milligrams compared with the adult dose of 20 to 40. Kids-strength Nexium is now available by prescription as a 20 mg time-release capsule; a 10 mg formulation — lime-flavored granules to be mixed with water — will be available later this year. Side effects include headache diarrhea abdominal pain and sleepiness.
Bloomberg.com: Investment Tools
Bloomberg – Mar 25, 2008
About Novogen Limited: Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is an Australianbiotechnology company that has patented isoflavone technology for thetreatment and prevention of degenerative diseases and disorders. ver the past ten years Novogen has conducted the largest and mostcomprehensive isoflavone clinical testing programs in the world. Novogen is involved in drug discovery and product development fordisorders that are commonly associated with aging and coordinates aninternational clinical research and development program with externalcollaborators hospitals and universities. For more informationvisit www. Last Updated: March 25 2008 08:01 EDT.
New academy launched to promote best practices in pharmaceutical…
Channel News Asia – Mar 25, 2008
This is to meet the growing demand for safe and effective health products such as medical devices drugs traditional medicines and cosmetics. The Singapore Academy of GxP Excellence (SAGE) will also promote best pharmaceutical practices. These will focus on the manufacturing sector as well as clinical research and the vigilance to ensure the safety of health products. Faculty members will be drawn from academia health authorities and major industry players in Singapore and overseas. The academy expects to train 300 to 500 industry executives every year. Associate Professor Chan Sui Yung who heads SAGE as well as the Department of Pharmacy at NUS said “It will be the first centre in this region that will harness state-of-the-art technologies to deliver global programmes efficiently and effectively. It will continually identify education and training gaps and provide relevant course content.
Supreme Court rules on insurance coverage
San Diego Union Tribune – Mar 25, 2008
Financial details were not disclosed. Kimmel Center's CE to resign for researchDr. Albert Deisseroth said he will resign as chief executive of the Sidney Kimmel Cancer Center in La Jolla so he can focus full time on clinical research as the institute's clinical director. Deisseroth has been CE of the institute for six years. He recently received Food and Drug Administration approval on two investigational new drug applications so that he can begin managing clinical trials on breast cancer and prostate cancer the institute said. The center is recruiting an interim CE. Baxter praises Halozyme's technologyBaxter International said that technology from San Diego biotechnology company Halozyme enabled positive results in an early stage trial of its therapy for immunodeficiency.
Medivation Announces Senior Management Promotions
Genetic Engineering News – Genetic Engineering News (press release) – Mar 25, 2008
Before joining the Company hewas a senior director of clinical development at Nuvelo Inc. Before that heserved as director of oncology development at SuperGen Inc. and as associatedirector of clinical research at Amgen Inc. (formerly Tularik Inc. ) wherehe led clinical development efforts for Tularik’s oncology trials. Early inhis career he was a clinical scientist and manager of market development andproduct evaluation at Theravance Inc.
